Insulin Resistance Clinical Trial
Official title:
Metformin Use to Improve Pregnancy Outcome in Women With Type 1 Diabetes. A Randomized Double-blind Placebo-controlled Multicenter Study.
Verified date | June 2023 |
Source | Tampere University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study investigates whether additional metformin medication in combination with regular insulin treatment will decrease the need of insulin for women with diabetes mellitus type 1 during pregnancy.
Status | Completed |
Enrollment | 101 |
Est. completion date | December 19, 2022 |
Est. primary completion date | December 19, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - a pregnancy of a woman with type 1 diabetes. Exclusion Criteria: - multiple pregnancy, significant underlying disease (hearth disease, kidney transplant, IBD (inflammatory bowel disease ), SLE (systemic lupus erythematosus ), diseases with use of high dosage corticosteroids (severe asthma or rheumatic disease), severe complications of diabetes (nephropathy, neuropathy, gastroparesis or severe retinopathy), substance abuse, smoking, BMI <18, strong early pregnancy nausea (=hyperemesis) |
Country | Name | City | State |
---|---|---|---|
Finland | Helsinki University Hospital | Helsinki | |
Finland | Central Finland Health Care District | Jyväskylä | |
Finland | Oulu University hospital | Oulu | |
Finland | Tampere University Hospital | Tampere | |
Finland | Turku University Hospital | Turku |
Lead Sponsor | Collaborator |
---|---|
Tampere University Hospital | Central Finland Hospital District, Helsinki University Central Hospital, Oulu University Hospital, Turku University Hospital |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the insulin need during pregnancy | The insulin dosage (IU/ml) in two weeks sets | from 5-10 gestational weeks until the delivery | |
Secondary | Blood glucose balance during pregnancy HbA1c | HbA1c (mmol/mol) | from gestational weeks 5 until the delivery | |
Secondary | Blood glucose balance during pregnancy AVG, SD, CV | mean blood glucose (mmol/l) level, standard deviation (SD) and the coefficient of variation of the blood glucose levels | from gestational weeks 5 until the delivery | |
Secondary | Change in the weight | Weight gain (g) during pregnancy | from gestational weeks 5 until the delivery | |
Secondary | Change in the blood pressure | Blood pressure (mmHg) | from gestational weeks 5 until the delivery | |
Secondary | Incidence of pre-eclampsia | Incidence of pre-eclampsia (%) | from gestational weeks 20 until the delivery | |
Secondary | Incidence hepatogestosis | Incidence hepatogestosis (%) | from gestational weeks 20 until the delivery | |
Secondary | Pregnancy complications | Incidence proteinuria (mg/mmol or mg/d) | from gestational weeks 5 until the delivery | |
Secondary | macrosomia | estimated fetal weight in ultrasound (grams) | from gestational weeks 20 until the delivery | |
Secondary | Pregnancy complications | incidence of miscarriage (intrauterine death before 22 weeks of gestation or fetal weigth under 500g) (%) | 12-22 weeks of gestation | |
Secondary | Pregnancy complications | incidence of intrauterine death (intrauterine death after 22 weeks of gestation or fetal weigth over 500g) (%) | 22-40 weeks of gestation | |
Secondary | Thigh fractional volume ultrasound | Fetal weight estimation (g) is specified by thigh fractional volume ultrasound program | from gestational weeks 20 until delivery | |
Secondary | Rate of the caesarean sections | Rate of the caesarean sections (%) | The delivery | |
Secondary | Labour | rate of spontaneous delivery (%) | The delivery | |
Secondary | Rate of the operative vaginal deliveries | Rate of the operative vaginal deliveries (%) | The delivery | |
Secondary | Rate of the shoulder dystocia | Rate of the shoulder dystocia (%) | The delivery | |
Secondary | Labor complications | rate of induced delivery (%) | The delivery | |
Secondary | Rate of the perineal tears | Rate of the perineal tears (%) | The delivery | |
Secondary | Postpartum bleeding | postpartum bleeding (ml) | The delivery | |
Secondary | Newborn variables (gestational age) | Rate of the premature deliveries (=deliveries before 37 weeks of gestation) (%) | After the delivery | |
Secondary | Newborn variables | weight of the newborn (g) | After the delivery | |
Secondary | Newborn outcome | Acidosis of the newborn (pH) | After the delivery | |
Secondary | Newborn outcome (intensive care) | The need of NICU (neonatal intensive care unit) treatment (days) | After the delivery | |
Secondary | Newborn outcome (hypoglycemia) | The occurrence of hypoglycemia (=plasma glucose under 2.6mmol/l or usage of iv glucose infusion) (%) | After the delivery | |
Secondary | Newborn outcome (Erb's) | Incidence of the Erb's paresis (%) | After the delivery | |
Secondary | Cost benefit calculations (sick leaves) | The need of sick leaves during pregnancy (days) | from gestational weeks 12 until delivery | |
Secondary | Cost benefit calculations (visits to maternity outpatient clinic or internal medicine policlinic) | The need of polyclinical controls during pregnancy (number of visits/pregnancy) | 14-40 weeks of gestation | |
Secondary | Cost benefit calculations (hospitalization) | The need of hospitalization during pregnancy (days/pregnancy) | 14-40 weeks of gestation | |
Secondary | Cost benefit calculations (all outpatient visits after delivery ) | The need of policlinical controls of the diabetic mother after the delivery (number of visits) | One year after the delivery | |
Secondary | Cost benefit calculations (hospitalization after delivery, all departments) | The need of hospitalization of the diabetic mother after the delivery (days) | Up to one year after the delivery | |
Secondary | Cost benefit calculations (all hospitalization of the child) | The need of hospitalization of the child (days) | Until the age of one year | |
Secondary | Cost benefit calculations (all policlinical controls of the child) | The need of policlinical controls of the child (number of visits) | Until the age of one year | |
Secondary | high sensitive-CRP | high sensitive-CRP (mg/l) | 7-10, 26-28 and 34-36 weeks of gestation | |
Secondary | lipids | cholesterol, high density lipoprotein, low density lipoprotein, triglyserids (mmol/l) | 7-10, 26-28 and 34-36 weeks of gestation | |
Secondary | Inflammatory markers | adiponectin, leptin, resistin, IL-6, TNF-a (pg/ml) | 7-10, 26-28 and 34-36 weeks of gestation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A |